Leukemia Clinical Trials

Showing 2701-2720 of 5,235 trials

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

NCT05346952

This is Phase 3, randomized, open-label, parallel controlled study designed to compare the efficacy and safety of TQB2450 in combination with platinum-containing chemotherapy followed by TQB2450 plus Anlotinib versus tislelizumab in combination with platinum-containing chemotherapy followed by tislelizumab in locally advanced (stage ⅢB/ⅢC), metastatic or recurrent ( Stage IV) non-squamous NSCLC cancer. The primary endpoint is Progression Free Survival (PFS) assessed by IRC.

Advanced Non-squamous Non-small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.390 participantsStarted Jan 2022

Beijing, Beijing Municipality, China

UNKNOWNPhase 3

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

NCT04229615

This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Placebo, as maintenance treatment, in patients with Stage III or IV ovarian cancer. Patients must have completed first-line platinum based regimen with Complete Response (CR) or Partial Response (PR). The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 3 portion of the study.

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.690 participantsStarted Jun 2020

Beijing, Beijing Municipality, China

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Related Searches

Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis

LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

Evaluation of Parent Intervention for Challenging Behaviour in Children With Intellectual Disabilities (EPICC-ID)

Conservative Treatment of Mallet Finger Injury

Stereotactic Radiotherapy (SBRT) in Patients With Locally Advanced Pancreatic Cancer (LAPC)

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Effect of Home Environment Regulation on Symptom Control and Quality of Life in Children With Allergic Rhinitis

Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia

Illness Management and Parental Adjustment to Cancer Treatment

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Vienna HIV Infection Via Sex Study

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Impact of Closely Grouped, Iterative Exposures to Suxamethonium During ECT on the Sensitization to NMBA and the Development of Protective Antibodies

Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy